Compounds used to treat arthritis

The shortcomings of the treatment of arthritis in the prior art were solved by using coumarin-7-O-β-D-glucoside, especially in reducing joint swelling and inflammatory factors, and joints were achieved Effective treatment of inflammation.

CN118649174BActive Publication Date: 2024-11-19BEIJING CHILDRENS HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411142901.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-20
Publication Date
2024-11-19
Estimated Expiration
2044-08-20

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat arthritis, especially by reducing joint swelling and inflammatory factors, providing effective treatment options.

Method used

Coumarin-7-O-β-D-glucoside as the main component is used to prepare pharmaceutical compositions for the treatment of arthritis, including drugs that reduce joint circumference and inflammatory factors, combined with other drugs for the treatment of arthritis and Pharmaceutically acceptable carriers, using a variety of routes of administration and dosage forms.

Benefits of technology

Coumarin-7-O-β-D-glucoside significantly reduces the joint circumference and swelling of arthritis rats, inhibits the level of inflammatory factors, provides new ideas for the treatment of arthritis, and has significant therapeutic effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118649174B_ABST
    Figure CN118649174B_ABST
Patent Text Reader

Abstract

The present invention discloses a compound for treating arthritis. The present application firstly finds that coumarin-7-O-β-D-glucoside can reduce the joint circumference of arthritis rats, relieve joint swelling of arthritis rats, and inhibit the level of inflammatory factors in arthritis rats, indicating that coumarin-7-O-β-D-glucoside has a therapeutic effect on arthritis, providing a new idea for the subsequent treatment of arthritis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a compound for treating arthritis. Background Art

[0002] Arthritis or joint pain generally refers to an inflammatory disease of the body's joints, usually accompanied by pain, swelling and stiffness. Arthritis can be caused by any one or more of several causes, including infection, trauma, degenerative disease, metabolic disease or disorder, or other unknown causes.

[0003] The synovium can become irritated and thicken in response to a number of insults believed to contribute to the development of arthritis, including trauma to the joint and / or dysfunction of the body's immune system. The consequences of these insults include overproduction and release of synovial fluid into the joint, which results in swelling in and around the joint area. The increase in volume is often accompanied by an increase in the concentration of proinflammatory cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor (TNF-α), histamine proteins, and degradative enzymes, such as matrix metalloproteinases (MMPs).

[0004] Therefore, providing a new arthritis treatment drug has important practical significance. Summary of the invention

[0005] To make up for the deficiencies of the prior art, the present invention provides a compound for treating arthritis.

[0006] To achieve the above object, the present invention adopts the following technical solution:

[0007] The first aspect of the present invention provides the use of coumarin-7-O-β-D-glucoside in preparing a pharmaceutical composition for treating arthritis.

[0008] Further, the treatment of arthritis includes any one or more of the following:

[0009] (1) Reduce joint circumference;

[0010] (2) Relieve joint swelling;

[0011] (3) Reduce the levels of inflammatory factors.

[0012] Furthermore, the inflammatory factors include one or more of IL1β, TNFα, IL6, IL26, IL22, IL20, IL10, IL38, IL33, and IL18.

[0013] Furthermore, the inflammatory factors include TNFα and / or IL6.

[0014] Furthermore, the arthritis is selected from rheumatoid arthritis.

[0015] The second aspect of the present invention provides the use of coumarin-7-O-β-D-glucoside in the preparation of a pharmaceutical composition for relieving joint swelling.

[0016] The third aspect of the present invention provides a pharmaceutical composition for treating arthritis / relieving joint swelling, the pharmaceutical composition comprising coumarin-7-O-β-D-glucoside.

[0017] Furthermore, the pharmaceutical composition also includes other drugs for treating arthritis.

[0018] Furthermore, the pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0019] Furthermore, the dosage form of the pharmaceutical composition includes solutions, tablets, powders, suspensions, emulsions, granules, capsules, pills, inhalants, gels, suppositories, creams, jellies, and sprays.

[0020] Furthermore, the administration routes of the pharmaceutical composition include intravenous administration, oral administration, mucosal administration, nasal administration, and rectal administration.

[0021] Advantages and beneficial effects of the present invention:

[0022] This application discovered for the first time that coumarin-7-O-β-D-glucoside can reduce the joint circumference of arthritic rats, relieve joint swelling of arthritic rats, and inhibit the level of inflammatory factors in arthritic rats, indicating that coumarin-7-O-β-D-glucoside has a therapeutic effect on arthritis and provides a new idea for the follow-up treatment of arthritis. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 This is a flowchart of rat modeling and drug administration;

[0024] Figure 2 is a schematic diagram of joint swelling in arthritic rats;

[0025] Figure 3 3A is a schematic diagram of the joint pathology of normal rats, 3B is a schematic diagram of the joint pathology of the model group, 3C is a schematic diagram of the joint pathology of rats in the coumarin-7-O-β-D-glucoside treatment group, and 3D is a schematic diagram of the joint pathology of rats in the 7-hydroxycoumarin glucuronide treatment group. DETAILED DESCRIPTION

[0026] The definitions of some terms used in this specification are provided below. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0027] The present invention provides the use of coumarin-7-O-β-D-glucoside in preparing a pharmaceutical composition for treating arthritis.

[0028] In one embodiment, coumarin-7-O-β-D-glucoside may also be called skimmin, and its CAS registration number is 93-39-0.

[0029] In one embodiment, coumarin-7-O-β-D-glucoside also includes a pharmaceutically acceptable salt of coumarin-7-O-β-D-glucoside. A pharmaceutically acceptable salt refers to any acid addition salt or base addition salt whose counterion is non-toxic to the patient at a pharmaceutical dose of the salt. The main body of pharmaceutically acceptable salts is well known in the art. If pharmaceutically acceptable salts of the compounds of the present application are used in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Among such acid salts are included, but are not limited to, the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, lucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate Salts, nicotinates, oxalates, pamoates, pectinates, persulfates, 3-phenyl-propionates, picrates, pivalates, propionates, succinates, tartrates, thiocyanates, toluenesulfonates, undecanoates, hydrohalides (e.g., hydrochlorides and hydrobromides), sulfates, phosphates, nitrates, sulfamates, malonates, salicylates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyl tartrates, ethanesulfonates, cyclohexylsulfamates, quinates, and the like. Pharmaceutically acceptable base addition salts include, but are not limited to, those derived from alkali metal or alkaline earth metal bases or conventional organic bases, such as triethylamine, pyridine, piperidine, morpholine, N-methylmorpholine, ammonium salts, alkali metal salts (such as sodium and potassium salts), alkaline earth metal salts (such as calcium and magnesium salts), salts with organic bases (such as dicyclohexylamine salts, N-methyl-D-glucamine), and salts with amino acids such as arginine, lysine.

[0030] In one embodiment, the types of arthritis include, but are not limited to, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gouty arthritis.

[0031] In a preferred embodiment, the arthritis is selected from rheumatoid arthritis.

[0032] In a specific embodiment, the rheumatoid arthritis is type II collagen-induced rheumatoid arthritis.

[0033] The present invention provides a pharmaceutical composition for treating arthritis / relieving joint swelling, which comprises coumarin-7-O-β-D-glucoside.

[0034] The pharmaceutical composition also includes other drugs for treating arthritis.

[0035] In one embodiment, other drugs for treating arthritis include but are not limited to celecoxib capsules, ibuprofen, loxoprofen sodium tablets, meloxicam, etoricoxib tablets, Voltaren sustained-release tablets, indomethacin tablets, diclofenac sodium sustained-release tablets, leflunomide tablets, methotrexate, iguratimod, sulfasalazine, tripterygium wilfordii glycosides tablets, glucosamine, chondroitin sulfate, hydroxychloroquine sulfate, etanercept, adalimumab, tocilizumab, secukinumab, prednisone acetate, methylprednisolone, calcium carbonate D3 tablets, calcitriol, and alendronate sodium.

[0036] The pharmaceutical composition also includes a pharmaceutically acceptable carrier.

[0037] In one embodiment, a pharmaceutically acceptable carrier is used to refer to a material that is compatible with a recipient, preferably a mammal, more preferably a human, and is suitable for delivering an active agent to a target site without terminating the activity of the agent. Toxicity or side effects (if any) associated with the pharmaceutically acceptable carrier are preferably commensurate with a reasonable risk / benefit ratio for the intended use of the active agent.

[0038] In one embodiment, pharmaceutically acceptable carriers include but are not limited to diluents, adhesives, surfactants, wetting agents, adsorption carriers, lubricants, fillers, and disintegrants. These pharmaceutically acceptable carriers are used to help the stability of the formulation or to help improve the activity or its biological effectiveness or to produce an acceptable taste or smell in the case of oral administration as needed. The preparations that can be used in such pharmaceutical compositions can be in the form of the original compound itself or optionally in the form of its pharmaceutically acceptable salt. The pharmaceutical composition thus prepared can be administered in any appropriate manner known to those skilled in the art as needed.

[0039] Among them, the diluent includes but is not limited to lactose, sodium chloride, glucose, urea, starch, and water.

[0040] Binders include, but are not limited to, starch, pregelatinized starch, dextrin, maltodextrin, sucrose, gum arabic, gelatin, methylcellulose, carboxymethylcellulose, ethylcellulose, polyvinyl alcohol, polyethylene glycol, polyvinylpyrrolidone, alginic acid and alginates, xanthan gum, hydroxypropyl cellulose and hydroxypropyl methylcellulose.

[0041] Surfactants include, but are not limited to, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, and cetyl alcohol.

[0042] Humectants include, but are not limited to, glycerin.

[0043] Adsorption carriers include, but are not limited to, bentonite, silica gel, kaolin, and bentonite.

[0044] Lubricants include, but are not limited to, zinc stearate, glyceryl monostearate, polyethylene glycol, talc, calcium and magnesium stearate, polyethylene glycol, boric acid powder, hydrogenated vegetable oil, sodium stearyl fumarate, polyoxyethylene monostearate, monolauric sucrose ester, sodium lauryl sulfate, magnesium lauryl sulfate, and magnesium dodecyl sulfate.

[0045] Fillers include, but are not limited to, mannitol (granular or powdered), xylitol, sorbitol, maltose, erythrose, microcrystalline cellulose, polymeric sugars, coupling sugars, glucose, lactose, sucrose, dextrin, starch, sodium alginate, laminarin powder, agar powder, calcium carbonate, and sodium bicarbonate.

[0046] Disintegrants include, but are not limited to, cross-linked vinyl pyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl methyl, cross-linked sodium carboxymethyl cellulose, and soybean polysaccharides.

[0047] In one embodiment, the route of administration of the drug includes but is not limited to intravenous administration, oral administration, mucosal administration, nasal administration, rectal administration, subcutaneous administration, intramuscular administration, transdermal administration or inhalation administration. In some embodiments, the drug of the present application can be administered by oral administration. For oral administration, for example, the drug can be formulated into conventional oral dosage forms such as capsules, tablets and liquid preparations such as syrups, elixirs and concentrated drops.

[0048] In one embodiment, the pharmaceutical composition can be manufactured by methods well known in the art, such as conventional granulation, mixing, dissolution, encapsulation, lyophilization or emulsification, etc. The pharmaceutical composition can be prepared in various forms, including but not limited to solutions, tablets, powders, suspensions, emulsions, granules, capsules, pills, inhalants, gels, suppositories, creams, jellies, and sprays.

[0049] In one embodiment, the solid dosage form for oral administration may include an acceptable adhesive, sweetener, disintegrant, diluent, flavoring agent, coating agent, preservative, lubricant and / or time delay agent (time delay agent) in human and veterinary pharmaceutical practice. Suitable adhesives include gum arabic, gelatin, corn starch, tragacanth gum, sodium alginate, carboxymethyl cellulose or polyethylene glycol. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharin. Suitable disintegrants include corn starch, methylcellulose, polyvinyl pyrrolidone, guar gum, xanthan gum, bentonite, alginic acid or agar. Suitable diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate or dicalcium phosphate. Suitable flavoring agents include peppermint oil, wintergreen oil, cherry, citrus or raspberry flavoring agents. Suitable coating agents include polymers or copolymers of acrylic acid and / or methacrylic acid and / or their esters, wax, fatty alcohol, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methylparaben, propylparaben or sodium bisulfite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.

[0050] In one embodiment, the liquid dosage form for oral administration may also include a liquid carrier in addition to the above-mentioned drugs. Suitable liquid carriers include water, oils such as olive oil, peanut oil, sesame oil, sunflower oil, safflower oil, peanut oil, coconut oil, liquid paraffin, ethylene glycol, propylene glycol, polyethylene glycol, ethanol, propanol, isopropanol, glycerol, fatty alcohol, triglyceride or a mixture thereof.

[0051] In one embodiment, the suspension for oral administration may further include a dispersant and / or a suspending agent. Suitable suspending agents include sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, sodium alginate or acetylethanol. Suitable dispersants include lecithin, polyoxyethylene esters of fatty acids such as stearic acid, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate, polyoxyethylene sorbitan mono- or di-oleate, -stearate or -laurate and the like.

[0052] In one embodiment, the pharmaceutical composition will change according to the desired effect. Therefore, the optimal content of the pharmaceutical composition of the present application can be easily determined by those skilled in the art, and can be adjusted according to the following various factors: the type and severity of the disease, the content of other components contained in the pharmaceutical composition, the type of preparation, the patient's age, body weight, general health, sex and diet, application time, route of administration, the secretion rate of the drug, the duration of treatment and the drug used simultaneously. The amount of the pharmaceutical composition should be determined considering the factors, and it can be applied once a day or in several portions. However, it should be understood that the actual dosage of the active ingredient should be determined considering various relevant factors, including the disease treated, the severity of the disease, the route of administration and the patient's weight, age and sex. Therefore, dosage does not limit the scope of the present invention in any way.

[0053] In one embodiment, treatment refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and may be performed for prevention or during clinical pathology. Desirable therapeutic effects include, but are not limited to, preventing disease occurrence or recurrence, alleviating symptoms, attenuating any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or relieving the disease state, and alleviating or improving prognosis.

[0054] The invention will be further described below in conjunction with specific examples. It should be understood that the specific embodiments described herein are presented by way of example and are not intended to limit the invention. The main features of the invention may be used in a variety of embodiments without departing from the scope of the invention.

[0055] Example

[0056] 1. Test methods

[0057] 1.1 Experimental animals and consumables

[0058] (1) 50 male SD rats, weighing 130-150 g, were purchased from Sibeifu (Beijing) Biotechnology Co., Ltd. After 3 days of adaptive feeding, they were used for drug administration and modeling.

[0059] (2) Modeling reagents: Chick type II collagen (Cat. No. 20011, purchased from Chondrex), Incomplete Freund's Adjuvant (Cat. No. 7002, purchased from Chondrex). Ultrasound was used to prepare the emulsion, which was prepared immediately before use. After preparation, 0.1 mL (containing 100 µg collagen / rat) was injected into the sole of the right foot of each rat. One week later, 0.1 mL of chicken type II collagen emulsion (containing 200 µg collagen / rat) was injected subcutaneously into the tail again. One week later, the rats were divided into groups according to their weight and degree of joint swelling, and drug treatment was given.

[0060] (3) Rat serum IL6 and TNFα ELISA detection kits, purchased from abcam, were used to evaluate whether the drug has an improving effect on systemic inflammation in the peripheral blood of arthritis rats.

[0061] 1.2 Grouping, modeling and drug administration process

[0062] (1) Grouping: The experiment was divided into 5 groups, with 8 rats in each group. The first group was the normal group, without modeling, and only the feet and tail were injected with the same dose of normal saline. The second group was the CIA model group, which was injected with chicken type II collagen emulsion. After successful modeling, the same dose of solvent, i.e. 0.5% CMC-Na solution, was gavaged every day. The third group was coumarin-7-O-β-D-glucoside, CIA modeling, once a day by gavage, the dose was 24 mg / kg. The fourth group was the 7-hydroxycoumarin glucuronide group, after CIA modeling, 24 mg / kg was gavaged every day. The fifth group was the 6-hydroxycoumarin group, after CIA modeling, 24 mg / kg was gavaged every day.

[0063] (2) Modeling and drug administration steps: The modeling was performed by two injections. 0.1 mL (containing 100 µg collagen / rat) was injected into the sole of the right foot of each rat. One week later, 0.1 mL of chicken type II collagen emulsion (containing 200 µg collagen / rat) was injected subcutaneously into the tail again. One week later, the rats were divided into groups according to their body weight and degree of joint swelling and given drug treatment. The modeling and drug administration test process is as follows: Figure 1 shown.

[0064] 1.3 Evaluation indicators

[0065] 1.3.1 Weight

[0066] From day 0 of adjuvant injection to the end of the experiment, the body weight changes of rats in each group were measured every 3 days.

[0067] 1.3.2 Clinical sign scoring

[0068] From day 0 to the end of the experiment, the following scores were performed on the joints of rats in each group every 3 days.

[0069] (1) Systemic score: Systemic scores were performed every 2 days after the onset of inflammation. The scoring criteria were as follows:

[0070] Ears: 0 = no nodules and redness, 1 = nodules and redness in one ear, 2 = nodules and redness in both ears;

[0071] Nose: 0 = no connective tissue swelling, 1 = obvious connective tissue;

[0072] Tail: 0 = no tubercle, 1 = tubercle;

[0073] Front paws: 0 = no swelling, 1 = swelling of one front paw, 2 = swelling of both front paws;

[0074] Hind paws: 0 = no swelling, 1 = swelling of one front paw, 2 = swelling of both front paws.

[0075] Each rat was scored a maximum of 8 points.

[0076] (2) Arthritis score: Scoring criteria for each paw:

[0077] Normal without erythema or swelling was scored as 0 points; erythema and slight swelling of the ankle joint was scored as 1; erythema and slight swelling from the ankle joint to the metatarsal joint and forefoot joint was scored as 2; further moderate swelling was scored as 3, and severe swelling was scored as 4. The total score of each rat's limbs was added together to form the rat arthritis index, with a maximum score of 16 points.

[0078] 1.3.3 Joint circumference

[0079] From the third day after the initial immunization to the end of the experiment, the joint swelling of the rats' hind feet was clinically scored and the circumference of the ankle joints of the two hind paws of the rats was measured using a vernier caliper.

[0080] 2. Experimental results

[0081] Table 1 Statistics of weight changes of rats in each group (mean + standard deviation)

[0082]

[0083] ###, P<0.001, compared with the normal group.

[0084] The results in Table 1 show that there was no statistical difference between the drug-treated groups and the model group.

[0085] Table 2 Joint circumference of rats in each group (mm, mean+standard deviation)

[0086]

[0087] ####, P<0.0001, compared with the normal group. *, P<0.05, compared with the model group.

[0088] The results in Table 2 show that compared with the normal group, the joint circumference of the model group rats increased significantly, indicating that the model was successfully established. The joint circumference of the coumarin-7-O-β-D-glucoside group was significantly reduced compared with the model group, and there was no statistical difference between the 7-hydroxycoumarin glucuronide group and the 6-hydroxycoumarin group compared with the model group.

[0089] Table 3 Statistics of joint swelling scores of rats in each group

[0090]

[0091] ####, P<0.0001, compared with the normal group. *, P<0.05, compared with the model group.

[0092] The results in Table 3 show that the joint swelling score of the coumarin-7-O-β-D-glucoside treatment group was significantly lower than that of the model group, while there was no statistical difference between the 7-hydroxycoumarin glucuronide administration group and the 6-hydroxycoumarin administration group and the model group. Figure 2 .

[0093] Table 4 Determination of TNFα and IL6 levels in serum

[0094]

[0095] ##, P<0.01, compared with the normal group. *, P<0.05, **, P<0.01, compared with the model group.

[0096] The results in Table 4 showed that the contents of TNFα and IL6 in the coumarin-7-O-β-D-glucoside group were significantly reduced compared with those in the model group.

[0097] Figure 3 The results of rat arthritis pathology showed that CIA rats had severe joint pathological damage, and 7-hydroxycoumarin glucuronide had no significant improvement on arthritis damage, but coumarin-7-O-β-D-glucoside had a significant improvement effect.

[0098] Specifically, Figure 3 A is a normal rat joint. Figure 3 B is the joint of the model group, Figure 3 B shows obvious lymphocyte infiltration at the edge of the joint, with blurred edges and covered with inflammatory secretions, proving that the model was successful. Figure 3C is the joint of rats in the coumarin-7-O-β-D-glucoside treatment group. The figure shows that the joint edge is relatively clear and the infiltration of inflammatory cells is reduced, suggesting that it has a therapeutic effect on CIA arthritis rats. Figure 3 D is the joint of rats in the 7-hydroxycoumarin glucuronide treatment group. The figure shows that the joint is severely damaged, the joint edge is blurred, the inflammatory cell infiltration is obvious, and there is no significant improvement.

[0099] In summary, coumarin-7-O-β-D-glucoside has significant therapeutic effect on the CIA rat arthritis model, significant anti-inflammatory effect, and significant effect on reducing inflammatory factors in the peripheral blood of rats, indicating that it is effective for arthritis and is significantly better than the other two compounds.

[0100] The description of the above embodiments is only used to understand the method and core idea of ​​the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.

Claims

1. Use of coumarin-7-O-β-D-glucoside in the preparation of a pharmaceutical composition for treating arthritis.

2. The use according to claim 1, characterized in that: The treatment of arthritis includes any one or more of the following: (1) Reduce joint circumference; (2) Relieve joint swelling; (3) Reduce the levels of inflammatory factors.

3. The use according to claim 2, characterized in that: The inflammatory factors include one or more of IL1β, TNFα, IL6, IL26, IL22, IL20, IL10, IL38, IL33, and IL18.

4. The use according to claim 1, characterized in that: The arthritis is selected from rheumatoid arthritis.

5. Use of coumarin-7-O-β-D-glucoside in the preparation of a pharmaceutical composition for relieving joint swelling.

6. The use according to any one of claims 1 to 5, characterized in that: The pharmaceutical composition also includes other drugs for treating arthritis.

7. The use according to claim 6, characterized in that: The pharmaceutical composition also includes a pharmaceutically acceptable carrier.

8. The use according to claim 7, characterized in that: The dosage forms of the pharmaceutical composition include solutions, tablets, powders, suspensions, emulsions, granules, capsules, pills, inhalants, gels, suppositories, creams, jellies, and sprays.

9. The use according to claim 7, characterized in that: The administration routes of the pharmaceutical composition include intravenous administration, oral administration, mucosal administration, nasal administration, and rectal administration.